Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MK-136
- Development stage
- Preclinical
- Lead developer
- Universität Greifswald
- Modality
- Small Molecules
01
Overview
MK-136 is a novel small molecule alpha-carboline derivative developed as an inhibitor of breast tumor kinase (Brk, also known as protein tyrosine kinase 6 or PTK6). Developed through a collaboration between the University of Greifswald and Martin Luther University Halle-Wittenberg, MK-136 targets PTK6 to modulate cellular signaling pathways involved in tumor cell migration, proliferation, and metastasis. In preclinical studies, MK-136 has demonstrated the ability to significantly impair both non-directional and directional migration of breast cancer cell lines, such as MDA-MB-231 and MDA-MB-468, highlighting its potential therapeutic utility in breast cancer.
02
Targets
PTK6 (Protein-tyrosine kinase 6)
Beyond the preview
Go deeper on MK-136.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MK-136.